These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 15964660

  • 1. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
    Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, Schima W, Göke B, Ochsenkühn T.
    J Hepatol; 2005 Aug; 43(2):303-9. PubMed ID: 15964660
    [Abstract] [Full Text] [Related]

  • 2. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 3. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients.
    de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ.
    Dig Liver Dis; 2008 Feb; 40(2):108-13. PubMed ID: 18083079
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG.
    Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
    [Abstract] [Full Text] [Related]

  • 6. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
    De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA.
    Scand J Gastroenterol; 2008 Feb; 43(5):604-8. PubMed ID: 18415755
    [Abstract] [Full Text] [Related]

  • 7. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W.
    Wien Klin Wochenschr; 2007 Feb; 119(17-18):519-26. PubMed ID: 17943403
    [Abstract] [Full Text] [Related]

  • 8. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia--a dual-centre experience.
    Ravikumara M, Hill FG, Wilson DC, Gillett PM, Thomas A, Brown R, Darbyshire PJ, McKiernan PJ.
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):535-8. PubMed ID: 16707977
    [Abstract] [Full Text] [Related]

  • 9. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
    Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA.
    Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.
    Laharie D, Vergniol J, Bioulac-Sage P, Diris B, Poli J, Foucher J, Couzigou P, Drouillard J, de Lédinghen V.
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):487-93. PubMed ID: 19940782
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Further experience with the use of 6-thioguanine in patients with Crohn's disease.
    Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J.
    Inflamm Bowel Dis; 2008 Oct; 14(10):1399-405. PubMed ID: 18521912
    [Abstract] [Full Text] [Related]

  • 16. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review.
    Toksvang LN, Schmidt MS, Arup S, Larsen RH, Frandsen TL, Schmiegelow K, Rank CU.
    PLoS One; 2019 Oct; 14(5):e0212157. PubMed ID: 31125338
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-Witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA.
    Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
    [Abstract] [Full Text] [Related]

  • 19. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP, Seinen ML, de Boer NK, van Bodegraven AA, Mulder CJ.
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.